Stem Cell Therapy in the Treatment of Patients with Ischemic Heart Failure
Emerson Perin, MD, PhD., Director, Clinical Research for Cardiovascular Medicine and the Medical Director of the Stem Cell Center, Texas Heart Institute, St. Luke’s Episcopal Hospital
Tuesday, November 1, 2011
5:45 p.m. – Networking Reception
6:30 p.m. – Presentation
Scientific advancements in the stem cell field can lead to new treatments and therapies for diseases and medical disorders for which we have few or no effective medications or treatment options. The emerging field of regenerative medicine capitalizes on unparalleled collaboration among leading scientists, requires innovative technologies and holds the potential to benefit society through improved health care, disease prevention and treatment.
The technologies, processes and equipment necessary to develop these new treatment options are of great scientific, technical and commercial interest and many companies are investing in this promising science and innovation across Texas today.
The Austin Forum on Science, Technology and Society and Texans for Stem Cell Research will co-host this event and are honored to present Emerson Perin, MD, PhD. Dr. Perin is the Director of Clinical Research for Cardiovascular Medicine and the Medical Director of the Stem Cell Center at the Texas Heart Institute at St. Luke’s Episcopal Hospital, as well as the Staff Interventional Cardiologist at St. Luke’s Episcopal Hospital. He is also Clinical Assistant Professor of Internal Medicine both at Baylor College of Medicine and The University of Texas Health Science Center at Houston.
Dr. Perin has provided innovative cardiovascular care for 20 years, focusing on minimally invasive interventional approaches to therapy. For more than 10 years, his major research interest has been the study of adult stem cells for the treatment of acute myocardial infarction, chronic heart failure, and peripheral vascular disease. Dr. Perin was the first investigator in the United States to receive approval from the Food and Drug Administration to inject stem cells directly into the hearts of patients suffering from heart failure.